<DOC>
	<DOCNO>NCT01898676</DOCNO>
	<brief_summary>A study stable epilepsy patient compare level valproic acid administration brand generic divalproex sodium extend release tablet .</brief_summary>
	<brief_title>A Study Stable Epilepsy Patients Comparing Brand Generic Divalproex Sodium Extended Release Tablets</brief_title>
	<detailed_description>Study consist screen visit , four treatment period final follow-up visit . Each treatment period consist four night in-house stay follow two outpatient visit . Each treatment period separate washout period . During treatment period , safety evaluation include vital sign , physical exam , safety laboratory test , weight measurement , electrocardiogram , adverse event collection concomitant medication record . Pharmacokinetic blood sample collect treatment period . Seizure activity record seizure diary study . A standardized high-fat , high-calorie meal serve prior dose treatment period .</detailed_description>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Valproic Acid</mesh_term>
	<criteria>Able understand , sign date inform consent form Male female 18 55 year old diagnosis epilepsy stable Body mass 18 34 kg/m , inclusive Is continuously receive fix dose AED medication ( ) minimum 30 day prior screen Stay dosage routine concomitant medication throughout study Healthy , determine prestudy medical history , vital sign , physical exam , ECG opinion investigator Normal renal function per laboratory test No clinically relevant lab . Negative hepatitis B , C HIV For female , negative pregnancy test Negative drug abuse alcohol Nonsmoker smoke within past six month . Some overthecounter medication may permit discretion investigator Able communicate well comply study procedure , requirement restriction History presence clinically significant medical disorder Have current psychiatric disorder History status epilepticus within 90 day screen Any condition investigator would feel could interfere safety subject study protocol . Taking three AED medication Use felbamate , aspirin , carbapenem antibiotic , rifampin , ritonavir , macrolide antibiotic , cholestyramine , and/or risperidone . Use investigational agent medical device within 30 day screen . History clinically significant drug allergy opinion investigator may compromise subject 's safety study result . History known hypersensitivity divalproex sodium excipients History alcohol drug abuse dependence past 5 year Consumed alcohol , caffeine xanthinecontaining food beverage within 48 hour prior clinic admission . Consumed grapefruit and/or grapefruit containing product within day prior admission clinic Day 1 agree consume grapefruit and/or grapefruit contain product duration study involvement Participated strenuous physical exercise within 72 hour admission clinic Day 1 agrees abstain duration study involvement . Acute illness screen and/or admission clinic Lactose intolerance unusual dietary habit . Blood donation within 8 week admission study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Extended-release divalproex sodium</keyword>
	<keyword>Depakote ER</keyword>
</DOC>